Atopic Keratoconjunctivitis – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Atopic Keratoconjunctivitis – Drugs In Development, 2024 report and make more profitable business decisions.
Atopic keratoconjunctivitis (AKC) is chronic allergic disease of eye. It is caused by atopy, a genetic condition that causes the immune system to produce more antibodies than normal in response to allergens. Symptoms include sensitivity to light, itching, burning, tearing, and red and hardened eyelids. AKC is usually diagnosed through clinical examination and a medical and family history, although a conjunctival biopsy may be helpful. Cold compresses and saline irrigation can lower the elevated tear pH. Only in severe cases should topical steroid therapy be used.
The Atopic Keratoconjunctivitis drugs in development market research report provide comprehensive information on the therapeutics under development for Atopic Keratoconjunctivitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Atopic Keratoconjunctivitis and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Atopic Keratoconjunctivitis | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Atopic Keratoconjunctivitis therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Atopic Keratoconjunctivitis pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Atopic Keratoconjunctivitis treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Allakos IncNexeos Bio
Regeneron Pharmaceuticals Inc
Satellos Bioscience Inc
Viatris Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Atopic Keratoconjunctivitis reports